Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Medica Superspecialty Hospital becomes the first private hospital in Eastern India to collaborate with UNICEF for breastfeeding workshop
Subscribe To Our Newsletter & Stay Updated
